Drugs / 5-(6-BENZOTHIAZOLYLMETHYLENE)-3,5-DIHYDRO-2-(((1S)-1-(METHOXYMETHYL)-3-METHYLBUTYL)AMINO)-4H-IMIDAZOL-4-ONE, (5Z)-

Follow last change Jun 2026 re-read 3 minutes ago

5-(6-BENZOTHIAZOLYLMETHYLENE)-3,5-DIHYDRO-2-(((1S)-1-(METHOXYMETHYL)-3-METHYLBUTYL)AMINO)-4H-IMIDAZOL-4-ONE, (5Z)-

also known as Leucettinib-21

Developed for: Alzheimer disease · Down syndrome
Investigated by: European Innovation Council · Fondation Jérôme Lejeune · France 2030 program · Perha Pharmaceuticals

today NCT06206824 · Ph 1

202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT06206824	Jan 2024 → Jun 2026	Alzheimer disease, Down syndrome	Perha Pharmaceuticals	Completed	No outcome recorded

Every value below carries the sentence it was read from. 2 sources stand behind the page.

Field	Value	Cited text
Known as	5-(6-BENZOTHIAZOLYLMETHYLENE)-3,5-DIHYDRO-2-(((1S)-1-(METHOXYMETHYL)-3-METHYLBUTYL)AMINO)-4H-IMIDAZOL-4-ONE, (5Z)-	ChEMBL registry synonym — accepted as the source's own label CHEMBL5426285 ↗
Known as	Leucettinib-21	ClinicalTrials.gov intervention name — accepted as the source's own label NCT06206824 ↗
Modality	Small molecule	— CHEMBL5426285 ↗
Route	Oral	“oral administration of Leucettinib-21” NCT06206824 ↗